文献速递类风湿关节炎脊柱关节炎

阿卡西普特(ALPN-101)双阻断ICOS与CD28揭示T细胞共刺激通路在炎症性关节炎中的非冗余作用

Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101).
PubMed 文献 · Arthritis Rheumatol · 2023-05-09

本研究通过体外受体结合与信号实验及胶原诱导性关节炎(CIA)模型,比较阿卡西普特(ALPN-101,一种可同时抑制CD28与ICOS共刺激的Fc融合蛋白)与CD28或ICOS单通路抑制剂的疗效。结果显示阿卡西普特可结合CD28和ICOS、阻断配体结合,在CIA模型中显著减轻疾病且效力强于阿巴西普,并对刺激后外周血单个核细胞的基因表达产生独特影响。作者认为同时抑制ICOS和CD28信号可能比单通路抑制剂更有效地减轻RA和PsA的炎症和/或疾病进展。

要点

  • 阿卡西普特可结合CD28和ICOS并阻止配体结合,体外活性匹配或超过单通路抑制剂单用或联用。
  • 在CIA模型中阿卡西普特显著减轻疾病,且效力强于阿巴西普。
  • 阿卡西普特对刺激PBMC的基因表达影响独特,不同于阿巴西普、prezalumab或二者联用。

核心结论

  • CD28和ICOS信号在炎症性关节炎中均起关键作用;同时抑制ICOS和CD28信号的治疗药物(如阿卡西普特)可能比单通路抑制剂更有效地减轻RA和PsA的炎症和/或疾病进展。

研究设计与样本

  • 体外受体结合与信号实验比较阿卡西普特与阿巴西普、贝拉西普(CTLA-4Ig)及prezalumab(抗ICOSL单克隆抗体)。
  • 在胶原诱导性关节炎(CIA)模型中比较阿卡西普特与阿巴西普的疗效。
  • 在健康供者或RA或PsA患者外周血单个核细胞(PBMC)与表达CD28和ICOS配体的人工抗原呈递细胞共培养的细胞因子和基因表达实验中比较阿卡西普特与上述抑制剂。

主要发现

  • 阿卡西普特可结合CD28和ICOS、阻止配体结合,并抑制人T细胞功能性相互作用,活性匹配或超过单通路CD28或ICOS共刺激抑制剂单用或联用。
  • 阿卡西普特在CIA模型中显著减轻疾病,且效力强于阿巴西普。
  • 阿卡西普特抑制刺激后PBMC在人工抗原呈递细胞共培养中的促炎细胞因子产生,并对基因表达产生不同于阿巴西普、prezalumab或二者联用的独特效应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: CD28 and inducible T cell costimulator (ICOS) appear to have nonredundant roles in T cell activation and adaptive immunity. We undertook this study to characterize in vitro and in vivo the therapeutic potential of acazicolcept (ALPN-101), an Fc fusion protein of a human variant ICOS ligand (ICOSL) domain designed to inhibit both CD28 and ICOS costimulation, in inflammatory arthritis. METHODS: Acazicolcept was compared in vitro with inhibitors of either the CD28 or ICOS pathways (abatacept and belatacept [CTLA-4Ig], prezalumab [anti-ICOSL monoclonal antibody]) in receptor binding and signaling assays, and in a collagen-induced arthritis (CIA) model. Acazicolcept was also compared in cytokine and gene expression assays of peripheral blood mononuclear cells (PBMCs) from healthy donors or rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients stimulated with artificial antigen-presenting cells (APCs) expressing CD28 and ICOS ligands*. RESULTS: Acazicolcept bound CD28 and ICOS, prevented ligand binding, and inhibited human T cell functional interactions, matching or exceeding the activity of CD28 or ICOS costimulatory single-pathway inhibitors tested individually or in combination. Acazicolcept administration significantly reduced disease in the CIA model and more potently than abatacept. Acazicolcept also inhibited proinflammatory cytokine production from stimulated PBMCs in cocultures with artificial APCs and demonstrated unique effects on gene expression distinct from those induced by abatacept, prezalumab, or a combination of both. CONCLUSION: Both CD28 and ICOS signaling play critical roles in inflammatory arthritis. Therapeutic agents such as acazicolcept that coinhibit both ICOS and CD28 signaling may mitigate inflammation and/or disease progression in RA and PsA more effectively than inhibitors of either pathway alone.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Dillon SR, Evans LS, Lewis KE, et al. Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101). Arthritis Rheumatol. 2023. PMID: 36862144. doi:10.1002/art.42484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。